Edition:
United States

Merck & Co Inc (MRK.N)

MRK.N on New York Stock Exchange

56.91USD
13 Dec 2017
Change (% chg)

$-0.16 (-0.28%)
Prev Close
$57.07
Open
$56.94
Day's High
$57.37
Day's Low
$56.65
Volume
4,343,136
Avg. Vol
3,210,469
52-wk High
$66.80
52-wk Low
$53.63

Chart for

About

Merck & Co., Inc. is a global healthcare company. The Company offers health solutions through its prescription medicines, vaccines, biologic therapies and animal health products. It operates through four segments: Pharmaceutical, Animal Health, Healthcare Services and Alliances. The Company's Pharmaceutical segment includes... (more)

Overall

Beta: 0.77
Market Cap(Mil.): $155,650.09
Shares Outstanding(Mil.): 2,727.35
Dividend: 0.48
Yield (%): 3.36

Financials

  Industry Sector
P/E (TTM): -- 31.96 15.25
EPS (TTM): -- -- --
ROI: -- 15.07 33.27
ROE: -- 16.58 16.35

BRIEF-Newlink Genetics, Bps And Merck Sharp & Dohme Amended License & Collaboration Agreement

* NEWLINK GENETICS - ON DEC 5, BPS AND MERCK SHARP & DOHME CORP AMENDED LICENSE & COLLABORATION AGREEMENT DATED NOV 21, 2014

Dec 11 2017

Merck raises stakes in lung cancer as rivals close in

LOS ANGELES Merck & Co Inc, maker of the only immunotherapy approved for patients newly-diagnosed with the most common type of lung cancer, could solidify its lead by playing the long game, even as rivals edge closer.

Dec 11 2017

BRIEF-Neon Therapeutics To Collaborate with Merk on Clinical Trial

* NEON THERAPEUTICS ANNOUNCES CLINICAL TRIAL COLLABORATION WITH MERCK

Dec 07 2017

BRIEF-Merck's Mavenclad (Cladribine Tablets) Approved For Relapsing-Remitting Multiple Sclerosis In Canada

* MERCK'S MAVENCLAD (CLADRIBINE TABLETS) APPROVED FOR RELAPSING-REMITTING MULTIPLE SCLEROSIS IN CANADA Source text for Eikon: Further company coverage:

Dec 04 2017

UPDATE 2-Health secretary nominee Azar says lowering drug prices a top priority

WASHINGTON, Nov 29 Alex Azar, a former drug industry executive and lobbyist nominated to run the U.S. Department of Health and Human Services, promised on Wednesday to lower drug prices and said he was unaware of any efforts to sabotage the healthcare law passed under former President Barack Obama.

Nov 29 2017

BRIEF-Merck Announces $10 Billion Share Repurchase Authorization

* MERCK ANNOUNCES INCREASED QUARTERLY DIVIDEND AND $10 BILLION SHARE REPURCHASE AUTHORIZATION

Nov 28 2017

As Brexit looms, UK pitches new industry plan, wins support from Merck, Qiagen

LONDON Britain pitched a new strategy for industry on Monday, pledging greater state intervention to tackle weak productivity and to help the world's sixth largest economy cope with the upheaval of leaving the European Union.

Nov 27 2017

As Brexit looms, UK pitches new industry plan, wins support from Merck, Qiagen

LONDON Britain pitched a new strategy for industry on Monday, pledging greater state intervention to tackle weak productivity and to help the world's sixth largest economy cope with the upheaval of leaving the European Union.

Nov 27 2017

UPDATE 2-As Brexit looms, UK pitches new industry plan, wins support from Merck, Qiagen

* Drug industry remains concerned about Brexit impact (Adds Prime Minister, Business Secretary comments, reaction)

Nov 27 2017

UK launches plan for industry as Brexit looms, wins Merck investment

LONDON, Nov 27 The British government launched a new strategy for industry on Monday, aiming to intervene in key sectors to tackle weak productivity and bolster businesses to counter any new problems caused by Brexit.

Nov 26 2017

Competitors

Earnings vs. Estimates